Russian Heart Failure Journal 2010year Prevalence of chronic heart failure’s treatment: five-year dynamics in Ryazan region


To access this material please log in or register

Register Authorize
2010/

Prevalence of chronic heart failure’s treatment: five-year dynamics in Ryazan region

Smirnova E. A., Yakushin S. S., Liferov R. A.

Keywords: dynamics of the prevalence, Ryazan region, CHF

DOI: 10.18087/rhfj.2010.1.1310

Urgency. Due to predicted increase of CHF morbidity and lack of data on survival improvement, it is important to study prevalence of CHF and approaches to drug therapy. Aim. To conduct 5-year monitoring of CHF epidemiology in Ryazan region. Materials and methods. Thi study is performed as part of national epidemiological study "EPOHA" and had three stages. The first stage included screening of representative sample of Ryazan region’s population (2 098 people), identifiying of patients with presumed heart failure I–IV FC. On the second stage (inhospital) all selected patients were examined in the cardiologic department. The diagnosis of CHF was verified on the basis of standard clinical symptoms assessment and echocardiography. On the third stage (in five years) the sample was examined again. Results. The first stage identified 233 patients (11.1 %) with signs of CHF I–IV FC. Inhospital phase allowed to verify the diagnosis in 176 patients (75.2 %), the prevalence of CHF was 7.9 %. Dominating FC in this population was I and II with preserved LV EF and diastolic dysfunction, type 1. Main causes of CHF were hypertension in conjunction with coronary artery disease (80.8 %) and DM (16.2 %). Repeated examination revealed increased number of patients with CHF I–IV FC (8,4 vs 11,6 %, p<0,001), prevalence of CHF III-IV FC remained the same (1,5 %). During five-year period positive changes in drug therapy were observed: the number of patients on regular drug therapy increased from 59,7 to 73,5 % (p<0,001), the rate of prescribing drugs having an influence on prognosis increased from 43,4 to 65,4 % (p<0,01).
  1. Мареев В. Ю. Основные достижения в области понимания, диагностики и лечения ХСН в 2003 году (часть 1). Журнал Сердечная недостаточность. 2004;5 (1):25–32.
  2. Мареев В. Ю., Даниелян М. О., Беленков Ю. Н. Сравнительная характеристика больных ХСН в зависимости от величины фракции выброса по результатам Российского многоцентрового исследования ЭПОХА–О–ХСН: снова о проблеме ХСН с сохранной систолической функцией левого желудочка. Журнал Сердечная Недостаточность. 2006;7 (4):164–171.
  3. Redfield MM. Heart failure – an epidemic of uncertain proportions. N Engl J Med. 2002;347 (18):1442–1444.
  4. Owan TE, Hodge DO, Herges RM et al. Trends in Prevalence and Outcome of Heart Failure with Preserved Ejection Fraction. N Engl J Med. 2006;355 (3):251–259.
  5. Фомин И. В., Беленков Ю. Н., Мареев В. Ю. и др. Распространенность хронической сердечной недостаточности в Европейской части Российской Федерации – данные ЭПОХА–ХСН. Журнал Сердечная Недостаточность. 2006;7 (3):112–115.
  6. Ho KK, Pinsky JL, Kannel WB et al. The epidemiology of heart failure: the Framingham study. J Am Coll Cardiol. 1993;22 (4 Suppl A):6A–13A.
  7. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society on Intensive Care Medicine (ESICM). Eur J Heart Fail. 2008;10 (10):933–989.
  8. Hunt SA, ACC / AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology / American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol. 2005;46 (6):e1–82.
  9. Cleland JGF, Swedberg K, Follath F et al. The EuroHeart Failure Survey programme-a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J. 2003;24 (5):442–463.
  10. Weir RAP; Mcmurray JJV; Taylor J; Brady AJB. Heart failure in older patients. Br J Cardiol. 2006;13 (4):257–266.
  11. Богданова С. М. Изучение эпидемиологии хронической сердечной недостаточности и вклада артериальной гипертензии в ее развитие в Чувашской республике: Автореф. дис. … канд. мед. наук. – Москва, 2008. – 19 с.
  12. Шакирова Р. М., Галявич А. С., Камалов Г. М., Кемалов Р. Ф. Эхокардиографические параметры при хронической сердечной недостаточности. Журнал Сердечная недостаточность. 2007;8 (2):84–85.
  13. Berry C, Hogg K, Norri J et al. Heart failure with preserved left ventricular systolic function: a hospital cohort study. Heart. 2005;91 (7):907–913.
  14. Щербинина Е. В., Бадин Ю. В., Вайсберг А. Р. и др. Динамика этиологических причин формирования ХСН в репрезентативной выборке Нижегородской области за 9 лет наблюдения (1998–2007 гг) // Тезисы III конгресса (IX конференции) Общероссийской общественной организации Общество специалистов по сердечной недостаточности «Сердечная недостаточность 2008». – М., 2008:108.
  15. Порошина Е. А., Тарловская Е. И. Эпидемиология артериальной гипер­тонии и сердечной недостаточности в Кировской области: динамика 2002–2007 // Тезисы III конгресса (IX конференции) Общероссийской общественной организации Общество специалистов по сердечной недостаточности «Сердечная недостаточность 2008». – М., 2008:11.
Smirnova E. A., Yakushin S. S., Liferov R. A. Prevalence of chronic heart failure’s treatment: five-year dynamics in Ryazan region. Russian Heart Failure Journal. 2010;11(1):63-68.

To access this material please log in or register

Register Authorize
Ru En